A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

Trial ID:

IRB-22-7924

Darren Sigal, M.D.

This study will test the safety and effectiveness of an investigational drug, OBI-3424, given once every three weeks by intravenous (IV) infusion in patients with advanced solid tumor cancer. This is the first study using OBI-3424 in humans.

Inclusion Criteria

*Be 18 years of age or older.
*Have tumor tissue collected from a previous or new biopsy to be submitted for eligibility analysis
*Be willing to use an effective method of contraception starting at screening until 6 months after the last dose of study drug
*Meet all other eligibility criteria

Contact Info:

• Clinical Research Services
• CRSLeadership@scrippshealth.org